FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286294880> ?p ?o ?g. }

• W4286294880 endingPage "12109" @default.
• W4286294880 startingPage "12109" @default.
• W4286294880 abstract "12109 Background: Up to 75% of patients with breast cancer report cognitive decline following chemotherapy. There is no standard of care prevention or treatment of cognitive problems in these patients. This trial (NCT04033419) examines the feasibility of using memantine to prevent cognitive decline during chemotherapy for breast cancer. Methods: We enrolled patients with stage I-III breast cancer scheduled to receive neo/adjuvant chemotherapy. Participants completed a cognitive battery (4 traditional neuropsychological measures and 3 computerized tests) and surveys of self-reported cognition (PROMIS Cognitive Function Short Form 8a) and other neuropsychiatric symptoms at pre-treatment (baseline) and 4 weeks after the last cycle of chemotherapy (post-assessment). Memantine (10 mg BID) was initiated within 1 week of starting chemotherapy and continued until the post-assessment. Adherence and adverse event (AE) monitoring occurred every 2-3 weeks during chemotherapy infusion visits. We used descriptive statistics to evaluate recruitment, retention, and tolerability, adherence, and acceptability of memantine. To evaluate objective cognition, we standardized individual measures using population-based data and averaged them to calculate composite scores of 1) global cognition; 2) attention, working memory, and executive function; and 3) learning and memory. Improvement or decline was defined as ≥ 0.5 SD change between the two assessments. For self-reported cognition, established cutpoints were used to define clinically meaningful change. Results: Of 154 eligible patients approached, 56 (36%) enrolled. Of 51 who completed the baseline assessment and started memantine, 44 (86%) completed the post-assessment; 2 remain active. Among evaluable participants, 92% reported taking ≥ 90% of scheduled doses. Only 36% self-reported cognitive decline, while no change was reported in 57% and improvement in 7%. Decline in objective cognitive domains was observed in 7 - 14% (see Table). There were 7 ≥ grade 3 AEs 2 were possibly related to memantine (diarrhea and hypokalemia). Only 3 participants expressed worry about memantine and only 2 felt that taking memantine disrupted their lives. Conclusions: Our findings suggest that memantine is a safe and feasible intervention for chemotherapy-related cognitive decline and may ameliorate cognitive loss. Randomized controlled trials are needed to determine its preliminary efficacy. Clinical trial information: NCT04033419. [Table: see text]" @default.
• W4286294880 created "2022-07-21" @default.
• W4286294880 creator A5000553093 @default.
• W4286294880 creator A5001873996 @default.
• W4286294880 creator A5005547611 @default.
• W4286294880 creator A5005764665 @default.
• W4286294880 creator A5007726590 @default.
• W4286294880 creator A5009401679 @default.
• W4286294880 creator A5016515991 @default.
• W4286294880 creator A5016973435 @default.
• W4286294880 creator A5034844578 @default.
• W4286294880 creator A5034934650 @default.
• W4286294880 creator A5039349890 @default.
• W4286294880 creator A5041313369 @default.
• W4286294880 creator A5044037578 @default.
• W4286294880 creator A5044678886 @default.
• W4286294880 creator A5052268581 @default.
• W4286294880 creator A5052641717 @default.
• W4286294880 creator A5068162188 @default.
• W4286294880 creator A5068848162 @default.
• W4286294880 creator A5074925418 @default.
• W4286294880 date "2022-06-01" @default.
• W4286294880 modified "2023-09-24" @default.
• W4286294880 title "A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer." @default.
• W4286294880 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.12109" @default.
• W4286294880 hasPublicationYear "2022" @default.
• W4286294880 type Work @default.
• W4286294880 citedByCount "0" @default.
• W4286294880 crossrefType "journal-article" @default.
• W4286294880 hasAuthorship W4286294880A5000553093 @default.
• W4286294880 hasAuthorship W4286294880A5001873996 @default.
• W4286294880 hasAuthorship W4286294880A5005547611 @default.
• W4286294880 hasAuthorship W4286294880A5005764665 @default.
• W4286294880 hasAuthorship W4286294880A5007726590 @default.
• W4286294880 hasAuthorship W4286294880A5009401679 @default.
• W4286294880 hasAuthorship W4286294880A5016515991 @default.
• W4286294880 hasAuthorship W4286294880A5016973435 @default.
• W4286294880 hasAuthorship W4286294880A5034844578 @default.
• W4286294880 hasAuthorship W4286294880A5034934650 @default.
• W4286294880 hasAuthorship W4286294880A5039349890 @default.
• W4286294880 hasAuthorship W4286294880A5041313369 @default.
• W4286294880 hasAuthorship W4286294880A5044037578 @default.
• W4286294880 hasAuthorship W4286294880A5044678886 @default.
• W4286294880 hasAuthorship W4286294880A5052268581 @default.
• W4286294880 hasAuthorship W4286294880A5052641717 @default.
• W4286294880 hasAuthorship W4286294880A5068162188 @default.
• W4286294880 hasAuthorship W4286294880A5068848162 @default.
• W4286294880 hasAuthorship W4286294880A5074925418 @default.
• W4286294880 hasConcept C118552586 @default.
• W4286294880 hasConcept C121608353 @default.
• W4286294880 hasConcept C126322002 @default.
• W4286294880 hasConcept C143998085 @default.
• W4286294880 hasConcept C169900460 @default.
• W4286294880 hasConcept C1862650 @default.
• W4286294880 hasConcept C197934379 @default.
• W4286294880 hasConcept C2778375690 @default.
• W4286294880 hasConcept C2779134260 @default.
• W4286294880 hasConcept C2779483572 @default.
• W4286294880 hasConcept C2779484449 @default.
• W4286294880 hasConcept C2908647359 @default.
• W4286294880 hasConcept C2984863031 @default.
• W4286294880 hasConcept C530470458 @default.
• W4286294880 hasConcept C71924100 @default.
• W4286294880 hasConcept C99454951 @default.
• W4286294880 hasConceptScore W4286294880C118552586 @default.
• W4286294880 hasConceptScore W4286294880C121608353 @default.
• W4286294880 hasConceptScore W4286294880C126322002 @default.
• W4286294880 hasConceptScore W4286294880C143998085 @default.
• W4286294880 hasConceptScore W4286294880C169900460 @default.
• W4286294880 hasConceptScore W4286294880C1862650 @default.
• W4286294880 hasConceptScore W4286294880C197934379 @default.
• W4286294880 hasConceptScore W4286294880C2778375690 @default.
• W4286294880 hasConceptScore W4286294880C2779134260 @default.
• W4286294880 hasConceptScore W4286294880C2779483572 @default.
• W4286294880 hasConceptScore W4286294880C2779484449 @default.
• W4286294880 hasConceptScore W4286294880C2908647359 @default.
• W4286294880 hasConceptScore W4286294880C2984863031 @default.
• W4286294880 hasConceptScore W4286294880C530470458 @default.
• W4286294880 hasConceptScore W4286294880C71924100 @default.
• W4286294880 hasConceptScore W4286294880C99454951 @default.
• W4286294880 hasFunder F4320332161 @default.
• W4286294880 hasIssue "16_suppl" @default.
• W4286294880 hasLocation W42862948801 @default.
• W4286294880 hasOpenAccess W4286294880 @default.
• W4286294880 hasPrimaryLocation W42862948801 @default.
• W4286294880 hasRelatedWork W182016951 @default.
• W4286294880 hasRelatedWork W2001206572 @default.
• W4286294880 hasRelatedWork W2077992747 @default.
• W4286294880 hasRelatedWork W2160269994 @default.
• W4286294880 hasRelatedWork W2161548387 @default.
• W4286294880 hasRelatedWork W245878504 @default.
• W4286294880 hasRelatedWork W2561267217 @default.
• W4286294880 hasRelatedWork W2565344414 @default.
• W4286294880 hasRelatedWork W3190803868 @default.
• W4286294880 hasRelatedWork W87706555 @default.
• W4286294880 hasVolume "40" @default.
• W4286294880 isParatext "false" @default.
• W4286294880 isRetracted "false" @default.

• next